Literature DB >> 10980999

Population screening for hemochromatosis: has the time finally come?

J C Barton1, R T Acton.   

Abstract

Hemochromatosis refers to a group of common heritable disorders among Western Caucasians which increase susceptibility for development of iron overload and its complications. These consequences are preventable by early detection and simple, relatively inexpensive treatment. Screening of appropriate populations to detect hemochromatosis before iron overload occurs is both effective and cost-effective. The primary goal of screening should be the ongoing detection of persons with hemochromatosis, especially healthy individuals whose risk to develop iron overload is great, in a context that provides appropriate preventive treatment, education, and counseling. Although related issues warrant further study, implementation of well-designed screening programs for hemochromatosis should not be delayed.

Entities:  

Mesh:

Year:  2000        PMID: 10980999     DOI: 10.1007/s11894-000-0047-3

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  51 in total

1.  If I had a gene test, what would I have and who would I tell?

Authors:  A G Motulsky
Journal:  Lancet       Date:  1999-07       Impact factor: 79.321

2.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis.

Authors:  J C Barton; W W Shih; R Sawada-Hirai; R T Acton; L Harmon; C Rivers; B E Rothenberg
Journal:  Blood Cells Mol Dis       Date:  1997       Impact factor: 3.039

4.  Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population.

Authors:  D S Marshall; D R Linfert; G J Tsongalis
Journal:  Int J Mol Med       Date:  1999-10       Impact factor: 4.101

5.  HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis.

Authors:  C Mura; O Raguenes; C Férec
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines.

Authors:  J P Frolkis; S J Zyzanski; J M Schwartz; P S Suhan
Journal:  Circulation       Date:  1998-09-01       Impact factor: 29.690

7.  Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri.

Authors:  S M McDonnell; A Hover; D Gloe; C Y Ou; M E Cogswell; L Grummer-Strawn
Journal:  Am J Med       Date:  1999-07       Impact factor: 4.965

8.  The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis.

Authors:  P C Adams; Y Deugnier; R Moirand; P Brissot
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

9.  Diagnosis of hemochromatosis probands in a community hospital.

Authors:  J C Barton; N H Barton; T J Alford
Journal:  Am J Med       Date:  1997-12       Impact factor: 4.965

10.  Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping.

Authors:  J C Barton; B E Rothenberg; L F Bertoli; R T Acton
Journal:  Genet Med       Date:  1999 Mar-Apr       Impact factor: 8.822

View more
  1 in total

1.  Quality of life utility values for hereditary haemochromatosis in Australia.

Authors:  Barbara de Graaff; Amanda Neil; Kristy Sanderson; Kwang Chien Yee; Andrew J Palmer
Journal:  Health Qual Life Outcomes       Date:  2016-02-29       Impact factor: 3.186

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.